HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia

Hao Geng, Chris T. Harvey, Janet Pittsenbarger, Qiong Liu, Tomasz (Tom) Beer, Changhui Xue, Zheng (David) Qian

    Research output: Contribution to journalArticle

    98 Citations (Scopus)

    Abstract

    Hypoxia-inducible factor 1α (HIF1α) is an essential part of the HIF-1 transcriptional complex that regulates angiogenesis, cellular metabolism, and cancer development. In von Hippel-Lindau (VHL)-null kidney cancer cell lines, we reported previously that HIF1α proteins can be acetylated and inhibited by histone deacetylase (HDAC) inhibitors or specific siRNA against HDAC4. To investigate the mechanism and biological consequence of the inhibition, we have generated stable HDAC4 knockdown via shRNA in VHL-positive normal and cancer cell lines. We report that HDAC4 regulates HIF1α protein acetylation and stability. Specifically, the HIF1α protein acetylation can be increased by HDAC4 shRNA and decreased by HDAC4 overexpression. HDAC4 shRNA inhibits HIF1α protein stability. In contrast, HDAC1 or HDAC3 shRNA has no such inhibitory effect. Mutations of the first five lysine residues (lysine 10, 11, 12, 19, and 21) to arginine within the HIF1α N terminus reduce protein acetylation but render the mutant HIF1α protein resistant to HDAC4 and HDACi-mediated inhibition. Functionally, in VHL-positive cancer cell lines, stable inhibition of HDAC4 decreases both the HIF-1 transcriptional activity and a subset of HIF-1 hypoxia target gene expression. On the cellular level, HDAC4 inhibition reduces the hypoxia-related increase of glycolysis and resistance to docetaxel chemotherapy. Taken together, the novel biological relationship between HDAC4 and HIF1α presented here suggests a potential role for the deacetylase enzyme in regulating HIF-1 cancer cell response to hypoxia and presents a more specific molecular target of inhibition.

    Original languageEnglish (US)
    Pages (from-to)38095-38102
    Number of pages8
    JournalJournal of Biological Chemistry
    Volume286
    Issue number44
    DOIs
    StatePublished - Nov 4 2011

    Fingerprint

    Hypoxia-Inducible Factor 1
    Acetylation
    Lysine
    Cells
    Small Interfering RNA
    Neoplasms
    Proteins
    Protein Stability
    docetaxel
    Cell Line
    Histone Deacetylase Inhibitors
    Chemotherapy
    Hypoxia
    Kidney Neoplasms
    Glycolysis
    Metabolism
    Gene expression
    Arginine
    Gene Expression
    Drug Therapy

    ASJC Scopus subject areas

    • Biochemistry
    • Cell Biology
    • Molecular Biology

    Cite this

    HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia. / Geng, Hao; Harvey, Chris T.; Pittsenbarger, Janet; Liu, Qiong; Beer, Tomasz (Tom); Xue, Changhui; Qian, Zheng (David).

    In: Journal of Biological Chemistry, Vol. 286, No. 44, 04.11.2011, p. 38095-38102.

    Research output: Contribution to journalArticle

    Geng, Hao ; Harvey, Chris T. ; Pittsenbarger, Janet ; Liu, Qiong ; Beer, Tomasz (Tom) ; Xue, Changhui ; Qian, Zheng (David). / HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia. In: Journal of Biological Chemistry. 2011 ; Vol. 286, No. 44. pp. 38095-38102.
    @article{328e9b6fd55c4a0fb2250d61ddc1408c,
    title = "HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia",
    abstract = "Hypoxia-inducible factor 1α (HIF1α) is an essential part of the HIF-1 transcriptional complex that regulates angiogenesis, cellular metabolism, and cancer development. In von Hippel-Lindau (VHL)-null kidney cancer cell lines, we reported previously that HIF1α proteins can be acetylated and inhibited by histone deacetylase (HDAC) inhibitors or specific siRNA against HDAC4. To investigate the mechanism and biological consequence of the inhibition, we have generated stable HDAC4 knockdown via shRNA in VHL-positive normal and cancer cell lines. We report that HDAC4 regulates HIF1α protein acetylation and stability. Specifically, the HIF1α protein acetylation can be increased by HDAC4 shRNA and decreased by HDAC4 overexpression. HDAC4 shRNA inhibits HIF1α protein stability. In contrast, HDAC1 or HDAC3 shRNA has no such inhibitory effect. Mutations of the first five lysine residues (lysine 10, 11, 12, 19, and 21) to arginine within the HIF1α N terminus reduce protein acetylation but render the mutant HIF1α protein resistant to HDAC4 and HDACi-mediated inhibition. Functionally, in VHL-positive cancer cell lines, stable inhibition of HDAC4 decreases both the HIF-1 transcriptional activity and a subset of HIF-1 hypoxia target gene expression. On the cellular level, HDAC4 inhibition reduces the hypoxia-related increase of glycolysis and resistance to docetaxel chemotherapy. Taken together, the novel biological relationship between HDAC4 and HIF1α presented here suggests a potential role for the deacetylase enzyme in regulating HIF-1 cancer cell response to hypoxia and presents a more specific molecular target of inhibition.",
    author = "Hao Geng and Harvey, {Chris T.} and Janet Pittsenbarger and Qiong Liu and Beer, {Tomasz (Tom)} and Changhui Xue and Qian, {Zheng (David)}",
    year = "2011",
    month = "11",
    day = "4",
    doi = "10.1074/jbc.M111.257055",
    language = "English (US)",
    volume = "286",
    pages = "38095--38102",
    journal = "Journal of Biological Chemistry",
    issn = "0021-9258",
    publisher = "American Society for Biochemistry and Molecular Biology Inc.",
    number = "44",

    }

    TY - JOUR

    T1 - HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia

    AU - Geng, Hao

    AU - Harvey, Chris T.

    AU - Pittsenbarger, Janet

    AU - Liu, Qiong

    AU - Beer, Tomasz (Tom)

    AU - Xue, Changhui

    AU - Qian, Zheng (David)

    PY - 2011/11/4

    Y1 - 2011/11/4

    N2 - Hypoxia-inducible factor 1α (HIF1α) is an essential part of the HIF-1 transcriptional complex that regulates angiogenesis, cellular metabolism, and cancer development. In von Hippel-Lindau (VHL)-null kidney cancer cell lines, we reported previously that HIF1α proteins can be acetylated and inhibited by histone deacetylase (HDAC) inhibitors or specific siRNA against HDAC4. To investigate the mechanism and biological consequence of the inhibition, we have generated stable HDAC4 knockdown via shRNA in VHL-positive normal and cancer cell lines. We report that HDAC4 regulates HIF1α protein acetylation and stability. Specifically, the HIF1α protein acetylation can be increased by HDAC4 shRNA and decreased by HDAC4 overexpression. HDAC4 shRNA inhibits HIF1α protein stability. In contrast, HDAC1 or HDAC3 shRNA has no such inhibitory effect. Mutations of the first five lysine residues (lysine 10, 11, 12, 19, and 21) to arginine within the HIF1α N terminus reduce protein acetylation but render the mutant HIF1α protein resistant to HDAC4 and HDACi-mediated inhibition. Functionally, in VHL-positive cancer cell lines, stable inhibition of HDAC4 decreases both the HIF-1 transcriptional activity and a subset of HIF-1 hypoxia target gene expression. On the cellular level, HDAC4 inhibition reduces the hypoxia-related increase of glycolysis and resistance to docetaxel chemotherapy. Taken together, the novel biological relationship between HDAC4 and HIF1α presented here suggests a potential role for the deacetylase enzyme in regulating HIF-1 cancer cell response to hypoxia and presents a more specific molecular target of inhibition.

    AB - Hypoxia-inducible factor 1α (HIF1α) is an essential part of the HIF-1 transcriptional complex that regulates angiogenesis, cellular metabolism, and cancer development. In von Hippel-Lindau (VHL)-null kidney cancer cell lines, we reported previously that HIF1α proteins can be acetylated and inhibited by histone deacetylase (HDAC) inhibitors or specific siRNA against HDAC4. To investigate the mechanism and biological consequence of the inhibition, we have generated stable HDAC4 knockdown via shRNA in VHL-positive normal and cancer cell lines. We report that HDAC4 regulates HIF1α protein acetylation and stability. Specifically, the HIF1α protein acetylation can be increased by HDAC4 shRNA and decreased by HDAC4 overexpression. HDAC4 shRNA inhibits HIF1α protein stability. In contrast, HDAC1 or HDAC3 shRNA has no such inhibitory effect. Mutations of the first five lysine residues (lysine 10, 11, 12, 19, and 21) to arginine within the HIF1α N terminus reduce protein acetylation but render the mutant HIF1α protein resistant to HDAC4 and HDACi-mediated inhibition. Functionally, in VHL-positive cancer cell lines, stable inhibition of HDAC4 decreases both the HIF-1 transcriptional activity and a subset of HIF-1 hypoxia target gene expression. On the cellular level, HDAC4 inhibition reduces the hypoxia-related increase of glycolysis and resistance to docetaxel chemotherapy. Taken together, the novel biological relationship between HDAC4 and HIF1α presented here suggests a potential role for the deacetylase enzyme in regulating HIF-1 cancer cell response to hypoxia and presents a more specific molecular target of inhibition.

    UR - http://www.scopus.com/inward/record.url?scp=80055077899&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=80055077899&partnerID=8YFLogxK

    U2 - 10.1074/jbc.M111.257055

    DO - 10.1074/jbc.M111.257055

    M3 - Article

    C2 - 21917920

    AN - SCOPUS:80055077899

    VL - 286

    SP - 38095

    EP - 38102

    JO - Journal of Biological Chemistry

    JF - Journal of Biological Chemistry

    SN - 0021-9258

    IS - 44

    ER -